The Janus face of HMGB1 in heart disease: a necessary update

Angela Raucci1 · Stefania Di Maggio1 · Francesco Scavello1 · Alessandro D’Ambrosio1,4 · Marco E. Bianchi2 · Maurizio C. Capogrossi3,5

Received: 17 July 2018 / Revised: 28 September 2018 / Accepted: 1 October 2018 / Published online: 10 October 2018
© The Author(s) 2018

Abstract
High mobility group box 1 (HMGB1) is a ubiquitous nuclear protein involved in transcription regulation, DNA replication and repair and nucleosome assembly. HMGB1 is passively released by necrotic tissues or actively secreted by stressed cells. Extracellular HMGB1 acts as a damage-associated molecular pattern (DAMPs) molecule and gives rise to several redox forms that by binding to different receptors and interactors promote a variety of cellular responses, including tissue inflammation or regeneration. Inhibition of extracellular HMGB1 in experimental models of myocardial ischemia/reperfusion injury, myocarditis, cardiomyopathies induced by mechanical stress, diabetes, bacterial infection or chemotherapeutic drugs reduces inflammation and is protective. In contrast, administration of HMGB1 after myocardial infarction induced by permanent coronary artery ligation ameliorates cardiac performance by promoting tissue regeneration. HMGB1 decreases contractility and induces hypertrophy and apoptosis in cardiomyocytes, stimulates cardiac fibroblast activities, and promotes cardiac stem cell proliferation and differentiation. Interestingly, maintenance of appropriate nuclear HMGB1 levels protects cardiomyocytes from apoptosis by preventing DNA oxidative stress, and mice with HMGB1 cardiomyocyte-specific overexpression are partially protected from cardiac damage. Finally, higher levels of circulating HMGB1 are associated to human heart diseases. Hence, during cardiac injury, HMGB1 elicits both harmful and beneficial responses that may in part depend on the generation and stability of the diverse redox forms, whose specific functions in this context remain mostly unexplored. This review summarizes recent findings on HMGB1 biology and heart dysfunctions and discusses the therapeutic potential of modulating its expression, localization, and oxidative-dependent activities.

Keywords Alarmin · Regeneration · Inflammation · Oxidative stress · Biomarker

Introduction
Cardiac diseases remain a leading cause of morbidity and mortality worldwide [1]. The adult heart is an organ with limited regenerative potential because of the low ability of cardiomyocytes (CMs) to proliferate after injury [2, 3]. The inflammatory response following cardiac damage consists of recruitment of immune cells that, in turn, guide the production of regenerative and healing mediators [4]. Cardiac repair occurs through the process of remodeling, involving mainly scarring orchestrated by cardiac fibroblasts (CFs), inflammatory cells and cardiomyocyte hypertrophy [4]. Strategies to enhance healing or prevent degeneration of a damaged heart are clinically relevant and represent an active research area.

High mobility group box 1 (HMGB1) is an architectural non-histone chromatin-binding protein regulating transcription, DNA replication and repair, and nucleosome structure...
and number [5–7]. Cells lacking HMGB1 contain 20% fewer nucleosomes and 30% more RNA transcripts genome-wide, and have an increased susceptibility to DNA damage [6]. In addition to its nuclear role, HMGB1 functions as an extracellular “alarmin” [8]. When cells die after trauma or infection, HMGB1 is passively released in the extracellular milieu, signals danger to the surrounding cells, activates innate and adaptive immunity and eventually promotes tissue repair [9, 10]. HMGB1 can also be secreted by activated cells after relocation from the nucleus to the cytosol [11]. Exogenous HMGB1 activity depends on the protein redox state and on several receptors including the receptor for advanced glycation endproducts (RAGE), Toll-like receptor 2 and 4 (TLR2-4) and C-X-C-chemokine receptor 4 (CXCR4) [12, 13]. Noteworthy, the dual location of HMGB1 may be functionally complementary, because HMGB1 secretion entails HMGB1 depletion in the nucleus [14]. As a major mediator of acute and chronic inflammation, extracellular HMGB1 plays a role in a variety of diseases and represents a promising pharmacologic target in multiple pathologic conditions [15].

In this review, we focus on the recent findings on HMGB1 redox functions and its role in cardiac dysfunctions.

**HMGB1: a multifunctional redox-sensitive protein**

**Structure and post-translational modifications of HMGB1**

HMGB1 is an evolutionary conserved chromatin-binding factor present in the nucleus of almost every cell type [16]. HMGB1 is essential for proper development since Hemgb1−/− mice die soon after birth [17]; however, inducible whole body Hmgb1−/− mice survive during adult life [18]. It belongs to the HMGB family and in mammals has three paralogs, HMGB2, HMGB3 and HMGB4; HMGB family members share the ability to bind DNA without sequence specificity and induce conformational and structural changes [5].

Human HMGB1 protein is composed of 215 amino acids organized in two DNA-binding domains, named A and B boxes, and a negatively charged C-terminal tail [19] (Fig. 1a). HMGB1 has two nuclear localization signals (NLS1 and NLS2) and two nuclear export signals (NESs) that imply the continuous shuttling of the protein between nucleus and cytoplasm; however, in physiological conditions, the nuclear concentration is higher than in the cytosol [11]. Post-translational modifications direct nucleus-cytoplasm shuttling of the protein in stressed/activated cells. NLS1 and NLS2 lysines acetylation by P300/CBP-associated factor (PCAF), CREB binding protein (CBP), and Histone acetyltransferase p300 (p300) reduce HMGB1 binding to the nuclear importin protein karyopherin-1, facilitating translocation to the cytosol [11]. Conversely, Sirtuin 1 (SIRT1) deacetylates HMGB1 promoting nuclear retention [20]. Translocation of HMGB1 is controlled also via serine/threonine phosphorylation catalyzed by the calcium/calmodulin-dependent protein kinase (CaMK) IV or the classical protein kinase C (CαPKC) [21, 22], and monomethylation of lysine-42 in neutrophils [23].

HMGB1 has three conserved cysteines in position 23 and 45 in the A box, which can form a disulfide bond, and in position 106 in the B box (Fig. 1a). Those cysteines are susceptible to oxidation that affects the extracellular activities of the protein [13, 24].

**HMGB1 is the archetype of DAMPs**

Inflammation is the first line of defense against pathogens or trauma, which are detected as pathogen-associated molecular pattern (PAMPs) and damage-associated molecular pattern (DAMPs) molecules, respectively [25]. PAMPs are microbial molecules carrying conserved molecular motifs that can activate cells of the innate and adaptive immunity [25, 26] after recognition by pattern-recognition receptors (PRRs), such as TLRs, RIG-I-like receptors (RLRs) and NOD-like receptors (NLRs) [26]. DAMPs are endogenous molecules with specific intracellular functions that are passively released by necrotic cells or actively secreted or exposed by stressed living cells after sterile injuries or infection; DAMPs, also named “alarmins”, are recognized by PRRs and signal danger, activate inflammation and eventually tissue repair [25]. Different DAMPs, including Adenosine Triphosphate (ATP), uric acid, Deoxyribonucleic acid (DNA), Ribonucleic acid (RNA), Interleukin-1α (IL1α), heat shock proteins (HSPs) and HMGB1, have been identified [10].

HMGB1 is mainly expressed in the nucleus regulating transcription, replication, DNA repair and nucleosome assembly [5–7]. Further, HMGB1 is rapidly released by damaged cells [27, 28] and actively secreted by immune cells [11]. In contrast, HMGB1 is retained by the condensed chromatin of apoptotic cells (Fig. 2) [28]. Unlike other pro-inflammatory cytokines, secreted HMGB1 is a delayed mediator of inflammation that is released late via nonclassical secretion pathways [29, 30]. Other danger signals or proinflammatory stimuli induce HMGB1 hyperacetylation and nuclear translocation [31] along with double-stranded RNA dependent kinase (PKR) autophosphorylation [32]. Activated PKR interacts with inflammasome components, like NACHT, LRR and PYD domains-containing protein 3 (NLRP3), and promotes inflammasome activation that eventually drives HMGB1 release via pyroptosis [32]. Thus, active secreted HMGB1 is hyperacetylated (Fig. 2).
Extracellular HMGB1 activates innate and acquired immunity, promotes tissue repair, and regeneration [9, 10, 33]. HMGB1 directly affects fibroblasts, monocytes/macrophages, dendritic and endothelial cells activation and migration [34–37]. Inhibition of extracellular HMGB1 attenuates inflammation and confers protection in several animal models of experimental diseases including sepsis [30], cardiac and liver ischemia/reperfusion injury [38, 39], diabetes [40], autoimmune diseases [41] and epilepsy [42]. Several inhibitors have been identified and developed to counteract HMGB1 (Table 1; reviewed in [15]). It is noteworthy that, in a variety of tissues exogenous HMGB1 can support regeneration [18, 44–46], wound-healing [47] and reparative angiogenesis [33] by inducing stem cell priming, proliferation, migration and differentiation, and by recruiting healing macrophages to the damaged tissue [18, 44, 45, 48–50].

Hence, HMGB1 is a DAMP that can elicit both harmful and beneficial responses after tissue damage. This pleiotropic activity depends on HMGB1 sensitivity to the environmental oxidizing conditions that induce complex redox post-translation modifications.

**HMGB1 redox state coordinates its extracellular activities through different receptors**

Based on the redox state of the cysteines, three redox forms of HMGB1 have been identified: fully reduced HMGB1 (fr-HMGB1) in which all cysteines are reduced, disulfide HMGB1 (ds-HMGB1) in which C23 and C45 are partially oxidized forming a disulfide bond, while the unpaired C106, that after further oxidation can give rise to the sulfonyl HMGB1 (ox-HMGB1) with cysteines carrying the sulfonyl group. The non-oxidizable HMGB1 3S mutant has been generated by substitution of cysteines with serine residues (S23–S45–S106).
stimulates pro-inflammatory cytokine/chemokine production in immune cells and is pro-angiogenic in endothelial cells [13, 24, 51, 52] (Fig. 2). A mutant of HMGB1, named 3S (Fig. 1b), in which cysteines have been substituted by serines, mimics fr-HMGB1 actions, likely because it is resistant to oxidation and cannot be converted to ds-HMGB1 or be inactivated by sulfonylation [13, 45, 53]. Ox-HMGB1 can be found in the late stage of the inflammatory process and is associated with the resolution/regenerative phase [24], and may influence the activation state of neutrophils [54].

The multifunctional activities of HMGB1 rely on the ability of the redox forms to bind different receptors, alone or in heterocomplex with others ligands [12]. The receptors most widely studied are RAGE, TLR2 and -4 and CXCR4 [12]. RAGE is a transmembrane receptor with structural features of adhesion molecules that recognizes several other proteins, i.e., advanced glycation endproducts (AGEs), S100/calgranulin proteins, amyloid β-peptides and extracellular matrix components [55, 56]. RAGE engagement signals through Mitogen-activated protein kinases (MAPKs) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), inducing cell activation, proliferation and migration [57]. RAGE is involved in a variety of pathologies mediated by HMGB1, and this axis represents an important potential target [58]. RAGE regulates HMGB1-induced cell adhesion and migration [59–61]. Although all redox forms of HMGB1 interact with RAGE, ds-HMGB1 binds with higher affinity [45, 62]. Interaction between RAGE and fr-HMGB1...
increases the transcription of the chemotactic gene stromal derived factor 1 (SDF-1) or C–X–C motif chemokine 12 (CXCL12) [13]. RAGE/ds-HMGB1 binding is necessary for platelet-dependent neutrophil activation and neutrophil extracellular traps (NETs) formation in thrombo-inflammatory lesions [62].

TLRs constitute a family of transmembrane molecules involved in host defense that have similar structure but differ in their subcellular localization and ligands [63]. TLR2 and TLR4 interact with HMGB1 leading to nuclear translocation of NF-κB and expression of pro-inflammatory cytokines in neutrophils and macrophages [64]. The TLR2/HMGB1 axis promotes natural killer (NK) and cancer stem cell activation [65, 66]. The HMGB1/nucleosome complex activates immune cells through TLR2 [67]. HMGB1/TLR4 or TLR2 axes contribute to regulate inflammation during lung and liver injury, epilepsy, cancer, and heart disease [42, 68–72]. It is not known which HMGB1 redox form binds to TLR2 and whether binding is direct or mediated by other TLR2 ligands. Ds-HMGB1 stimulates cytokine/chemokine production in inflammatory cells through binding to TLR4 [24, 73] via formation of a complex with CD14 and TLR4 adaptor myeloid differentiation factor 2 (MD-2) [73–75] (Fig. 2). Prevention of ds-HMGB1/MD-2 interaction abrogates cytokine induction and protects against liver injury, chemical toxemia and sepsis [73].

CXCR4 is a receptor for SDF-1/CXCL12, an important chemotactic stimulus for leukocytes [76]. Fr-HMGB1 forms a heterocomplex with CXCL12 that protects CXCL12 from degradation and is responsible for CXCR4-mediated migration in mouse embryonic fibroblasts (MEFs), human cardiac fibroblasts (hFbs), macrophages, dendritic cells, and myoblasts [13, 36, 53, 77] (Fig. 2). Fr-HMGB1 promotes muscle, skeletal, hematopoietic and liver regeneration through CXCR4, at least in part by recruiting tissue healing macrophages and promoting the transition of resident stem cells from the G₀ to the G_alert phase, thereby accelerating their proliferation, migration and differentiation [13, 45] (Fig. 2). Interestingly, 3S interacts directly with CXCR4 with no need for CXCL12, and induces a conformational state of CXCR4 different from that triggered by CXCL12 [45, 53]. Accordingly, 3S exhibits an efficient Non-Receptor Tyrosine Kinase (Src)-mediated chemotactic activity even in the absence of CXCL12 [53]. The resistance to oxidative conditions and the direct binding to CXCR4 can explain the higher effectiveness of 3S relative to fr-HMGB1 [45, 53] (Fig. 3). Moreover, 3S binds inefficiently to TLR4/MD-2 and RAGE and does not exhibit pro-inflammatory properties [45, 53].

Hence, HMGB1 undergoes progressive redox modifications necessary to start, regulate and resolve the inflammatory response, but also to coordinate tissue repair and regeneration through the recognition of different receptors and interactors.

### HMGB1 in cardiac dysfunction

*Hmgbl* null mutations are lethal and mice die soon after birth with complex pleiotropic features, indicating that HMGB1 contributes to development and perinatal survival [17]. So far, there are no studies describing the mechanisms by which HMGB1 may affect proper heart development. On the other hand, HMGB1 seems to be dispensable for cellular homeostasis and proper organ function in the adult organism [18, 78]. In particular, mice with a cardiomyocyte-specific *Hmgbl* deletion do not show structural abnormalities or alterations in cardiac function and contractility and long-term survival [79]. Transgenic mice...
with cardiomyocyte-specific overexpression of HMGB1 (cHMGB1-Tg) display no significant differences in cardiac performances and plasma levels of HMGB1 in physiological conditions compared to the wild-type animals, however, after the induction of a cardiac damage they are partially protected from developing heart dysfunctions [80].

**Ischemic heart diseases**

**Myocardial infarction**

Myocardial infarction (MI) is an ischemic insult resulting in loss of cardiomyocytes that are replaced by scar tissue [4]. Soon after MI, stressed cardiomyocytes release specific DAMPs that induce an acute and transient inflammatory response by activating PRRs [81]. Inflammatory cells clear debris from the infarcted area and secrete growth factors to activate myofibroblasts and vascular cells and initiate wound healing and tissue remodeling [4]. Finally, anti-inflammatory signals terminate leukocyte invasion and resolve inflammation, promoting tissue repair [4].

During MI, HMGB1 acts as a DAMP, modulates inflammation and functions as a regenerative factor. In a mouse model of MI induced by permanent coronary artery ligation, HMGB1 serum levels rapidly increase because of cardiac tissue necrosis. In the infarct zone HMGB1 expression peaks several days after MI: in the acute phase it is mainly localized in infiltrating inflammatory cells and later in CFs [82].

Inhibition of extracellular HMGB1 after the infarct worsens cardiac dysfunction (Table 2). Indeed, injection of an anti-HMGB1 antibody 24 h post-infarction causes a reduction in inflammation and a marked infarct scar thinning [82]. Conversely, cHMGB1-Tg mice when undergoing infarction exhibit a smaller infarct size, preserved cardiac function and improved survival [80]. Infarcted cHMGB1-Tg animals show enhanced angiogenesis induced by increased mobilization and migration of bone marrow cells to the heart, their differentiation into endothelial progenitor cells and subsequent engraftment as vascular endothelial cells in new capillaries and arterioles [80, 83]. Similarly, mice injected with fr-HMGB1 in the ventricular tissue bordering the viable myocardium after MI exhibit improved Left Ventricular (LV) function due to neo-angiogenesis and a partial repopulation of the LV wall by newly formed cardiomyocytes derived from resident cardiac stem cells (CPCs; Fig. 4) [44, 53]. HMGB1 also attenuates cardiomyocyte apoptosis and stimulates their survival by inducing cell autophagy through AMP-activated protein kinase (AMPK) activation and inhibition of mammalian target of rapamycin complex 1 (mTORC1) [84]. Transcriptomic analysis confirmed that fr-HMGB1 enhances the expression of genes involved in endothelial cell migration and proliferation, stem cell differentiation and cardiomyocyte contraction [85]. HMGB1 also activates Translocation-Associated Notch Protein TAN-1 (Notch1) in the cardiomyocytes and increases the number and cardiomyogenic differentiation of CPCs [85]. HMGB1 influences CPC behavior in a paracrine manner as well, since conditioned medium from HMGB1-treated CFs induces CPC proliferation, migration and differentiation into endothelial cells [44, 86].

Notably, the oxidizing environment generated after MI affects HMGB1 activities, since the injection of the non-oxidizable 3S mutant in infarcted mice worsens cardiac performance and enhances collagen deposition by increasing the number of myofibroblasts. This is possibly to a direct and sustained over-activation of CXCR4 (Fig. 4), as 3S is active at lower concentrations relative to fr-HMGB1 and in oxidizing conditions in stimulating hCFb migration and Src phosphorylation [53] (Fig. 3).
| Experimental disease model | HMGB1 (redox form) | HMGB1 antagonist | Route of administration | Treatment effect | References |
|----------------------------|-------------------|------------------|-------------------------|-----------------|------------|
| MI/rat                     | –                 | 10 mg/Kg/day Poly anti-HMGB1 | Subcutaneously 24 h after MI for 7 days | Detrimental—expansions of infarct scar and reduced inflammation | [78] |
| MI/cHMGB1-Tg mouse         | Cardiomyocytes overexpression of HMGB1 | – | – | Beneficial—reduced remodeling and increased angiogenesis | – | [79, 80] |
| MI/mouse                   | 200 ng HMGB1 (fr-HMGB1) | – | Injections in the peri-infarcted area 4 h after MI | Beneficial—reduced remodeling and enhanced cardiac and vascular regeneration | – | [44, 53, 81, 82] |
| MI/mouse                   | 200 ng non-oxidable 3S mutant | – | Injections in the peri-infarcted area 4 h after MI | Detrimental—increased collagen deposition and decreased angiogenesis | – | [53] |
| MI-Chronic HF/mouse        | 200 ng wtHMGB1 (fr-HMGB1) | – | Injections in the peri-infarcted area 2 weeks after MI | Beneficial—reduced remodeling and enhanced cardiac and vascular regeneration | – | [85] |
| MI-Chronic HF/rat          | 2.5 μg HMGB1 | – | 3 weeks after MI in the peri-infarcted area | Beneficial—reduced fibrosis | – | [84] |
| I/R mouse; 30 min occlusion-48 h reperfusion | 10 μg HMGB1 | 400 μg BoxA | i.p. 1 h before I/R | Detrimental—enhanced fibrosis and inflammation | Protective—reduced necrosis, fibrosis and inflammation | [38] |
| I/R mouse; 30 min occlusion-24 h reperfusion | 600 μg HMGB1 | 300 μg BoxA | i.p. 1 h before I/R | No effect | Protective—reduced necrosis and inflammation | [69] |
| I/R mouse; 30 min occlusion-24 h reperfusion | – | 200 μg Poly anti-HMGB1; 70 μg mAb anti-TLR2 | i.p. 1 h before I/R | – | Protective—reduced cardiac necrosis and apoptosis | [68] |
| I/R rat; 30 min occlusion-1 h reperfusion | – | mAb anti-HMGB1 | Intravenous before reperfusion | – | Detrimental—increased cardiac necrosis, inflammation and infarct size | [88] |
| I/R rat; 30 min occlusion-4 h reperfusion | 200 μg/Kg HMGB1 | – | i.p. 24 h before I/R | Protective—reduced infarct size and inflammation | – | [100] |
| TAC/cHMGB1-Tg mice         | Cardiomyocytes overexpression of HMGB1 | – | – | Protective—reduced LV dysfunction, expression of hypertrophic markers and oxidative DNA damage | – | [107] |
| TAC/mouse                  | 200 ng HMGB1 | 200 ng BoxA | Cardiac injection before ligation | Detrimental—increased cardiac hypertrophy and HF/ | Protective—reversion of cardiac hypertrophy | [106] |
| Single dose of Dox i.p. 10 mg/kg/mouse | – | 20 mg/kg BoxA | i.p. for 5 days starting 4 h after the Dox treatment | – | Protective—reduced apoptosis | [72] |
### Table 2 (continued)

| Experimental disease model                      | HMGB1 (redox form)          | HMGB1 antagonist | Route of administration                  | Treatment effect                                                                 | References |
|------------------------------------------------|-----------------------------|------------------|------------------------------------------|----------------------------------------------------------------------------------|------------|
| Single dose of Dox i.p. 17.5 mg/kg/HMGB1-Tg mouse | Cardiomyocytes overexpression of HMGB1 | –                | –                                        | Protective—reduced apoptosis, LV dilation and remodeling                          | [111]      |
| CMD induced by streptozocin/mouse              | –                           | 300 μg BoxA      | Daily i.p. for 5 weeks after onset of hyperglycemia | –                                                                                | [116]      |
| I/R in CMD induced by streptozocin/mouse       | –                           | 400 μg BoxA      | Daily i.p. starting 1 h before I/R for 5 days after onset of hyperglycemia | –                                                                                | [113]      |
| ISO-induced cardiac fibrosis                   | –                           | 10 mg/kg Gly     | Daily i.p. for 15 days 1 h before ISO injection | –                                                                                | [119]      |
| EAM (MyHC)/mouse                               | –                           | 400 μg mAb anti-HMGB1 | i.p. daily                                | –                                                                                | [122]      |
| EAM (TnI)/mouse                                | –                           | 10 mg/Kg Gly or 50 μg mAb 2G7 anti-HMGB1 | i.p. daily                                | –                                                                                | [124]      |
| LPS i.p. 10 mg/Kg/mouse                        | –                           | 600 μg BoxA or 100 mg/Kg Gly    | i.p. 4 h after LPS                       | –                                                                                | [127]      |

*cHMGB1-Tg* HMGB1 cardiac overexpression, *DCM* diabetic cardiomyopathy, *Dox* doxorubicin, *DNA* deoxyribonucleic acid, *EAM* experimental autoimmune myocarditis, *fr-HMGB1* fully reduced HMGB1, *Gly* glycyrrhizin; *HF* heart failure, *I/R* ischemia/reperfusion, *ISO* isoproterenol, *LPS* lipopolysaccharide, *LV* left ventricular, *mAb* monoclonal antibody, *MI* myocardial infarction, *MyHC* cardiac myosin heavy chain, *Poly* polyclonal antibody, *TAC* transverse aortic constriction, *TLR* toll-like receptor, *wtHMGB1* wild type HMGB1
HMGB1 treatment improves cardiac recovery also in the context of post-MI chronic failing heart by attenuating inflammation in the peri-infarcted area and reducing LV remodeling and fibrosis [87, 88]. In this context, HMGB1 lowers collagen deposition by directly affecting Matrix Metalloproteinase 9 (MMP9) activity and Metalloproteinase Inhibitor 3 (TIMP3) expression through the induction of the microRNA (miR)-206 in hypoxic CFs [88].

Hence, in both acute and chronic MI higher levels of cardiac HMGB1 or exogenous administration of fr-HMGB1 elicits protective effects by modulating inflammation, enhancing cardiomyocytes regeneration and angiogenesis, and reducing fibrosis (Table 2). Interestingly, the progressive oxidation of fr-HMGB1 seems important to orchestrate correctly tissue healing after infarction. The involvement of HMGB1 receptors in MI has not been studied yet.

Ischemia/reperfusion (I/R)

In ischemic tissues, the decrease in blood supply leads to a deficit in oxygen and nutrients. In the heart, if ischemia is prolonged, cardiomyocytes die of necrosis and apoptosis. Reperfusion restores blood flow and can mitigate some of the deleterious effects of ischemia, but at the same time, is responsible for the massive leukocytes recruitment and the excessive production of free oxygen radicals at the injury site, which can cause additional damage exceeding the initial ischemic injury [89].

Several studies report an increase of circulating as well as myocardial HMGB1 levels in experimental models of I/R [38, 90, 91]. Circulating HMGB1 derives from necrotic cardiomyocytes and active secretion by hypoxic cardiac and infiltrating inflammatory cells [38, 68]. Myocardial HMGB1 expression increases soon after ischemia and remains high several days after reperfusion [38, 92]. Upregulation and release of HMGB1 has been described also in isolated neonatal murine cardiomyocytes (NMCs) after hypoxia/reoxygenation (H/R) [38, 68, 92]. Extracellular HMGB1 alone or in concert with Tumor Necrosis Factor-α (TNFα) enhances H/R-induced cardiomyocyte apoptosis through the activation of Jun N-terminal kinase (JNK) and NF-κB via TLR2/4. Recently, Tian et al. described a signaling axis involving cardiac HMGB1 and splenic RAGE showing that circulating HMGB1 released from necrotic cardiac tissue after prolonged ischemic insult activates splenic leucocytes through RAGE to produce neutrophils that migrate to the injured myocardium [93]. This contributes to infarct exacerbation during reperfusion [93]. Oxidative and nitrosative stress control HMGB1 expression and release during I/R [90, 94]. The 5,10,15,20-tetrakis(2,4,6-trimethyl-3,5-sulfonatophenyl)porphyrinato iron III (FeTPPS), a selective peroxynitrite scavenger, significantly reduces myocardial HMGB1 expression and tissue injury triggered by I/R [90]. Similarly, pharmacological or herbal compounds, like geranylgeranylacetone, osthole, isoproteranol, asperosaponin, astilbin, minocycline, quercetin, and celastrol prevent HMGB1 upregulation and exert a protective effect [95–102].

Several HMGB1 inhibitors have been tested during I/R; however, the timing (pre-ischemic or post-ischemic phase), the dose or the mode of their administration appeared crucial in determining the final effect (Table 2; Fig. 5). Blocking HMGB1 before I/R exerts a protective action [38, 69,
Injection of BoxA, an inhibitory domain of HMGB1, 1 h before I/R injury improves recovery of heart function by reducing cardiac necrosis, infarct size and inflammation [38]. Conversely, pre-treatment with high doses of recombinant HMGB1 is detrimental [38]. The pro-inflammatory activity of HMGB1 depends on RAGE/MAPKs/NF-κB and TLR2 activation since Rage−/− and Tlr2−/− mice are protected from I/R injury even after administration of HMGB1 [38, 69]. The two receptors are likely to cooperate in these experimental settings.

The N-terminal lectin-like domain (LLD) of thrombomodulin is known to sequester HMGB1 and prevent receptor binding [68, 104]. Mice lacking LLD showed elevated levels of HMGB1 expression in cardiac cells after I/R and developed larger infarcts due to massive cardiac inflammation and apoptosis. This phenotype is reverted with antibodies against HMGB1 or TLR2, or soluble LLD injected before I/R [68].

Intravenous administration of an anti-HMGB1 antibody in the post-ischemic phase and before reperfusion in rats determines an enlargement of the infarct size and increased levels of TNFα and the inducible nitric oxide synthase (iNOS) [91]. Accordingly, HMGB1-Tg mice undergoing TAC show higher survival and attenuated LV dilatation, systolic dysfunction, expression of hypertrophic markers and oxidative DNA damage (Table 2) [110].

In contrast, extracellular HMGB1 stimulates hypertrophy in isolated NRCMs, by increasing the cell surface and expression of Atrial Natriuretic Peptide through partial activation of calcineurin [108, 111]. Administration of BoxA in the heart reverses cardiac hypertrophy and delays heart failure (HF) induced by pressure overload, while recombinant HMGB1 aggravates it (Table 2) [109]. The ability of HMGB1 to induce cardiac hypertrophy does not involve RAGE, since Rage−/− mice still develop cardiac hypertrophy after TAC [108].

Thus, HMGB1 may play dual functions in the context of cardiac hypertrophy depending on its subcellular localization. Preservation of intracellular HMGB1 levels prevents cardiac hypertrophy possibly by avoiding oxidative DNA stress, whereas extracellular HMGB1 promotes CM hypertrophy through an unknown receptor.

No published studies concerning the role of HMGB1 in hypertrophic obstructive cardiomyopathy are available so far. However, it is possible that the findings described above will be relevant to all conditions associated with an increase in myocardial mass, including hypertrophic obstructive cardiomyopathy.

### Anthracycline-induced cardiomyopathy

The survival rate of cancer patients has increased in the last years due to chemotherapy. However, many chemotherapeutic agents are cardiotoxic, eventually influencing the quality of life of survivors [112]. Anthracyclines such as Doxorubicin (Dox) and Adriamycin (ADR) are widely used and effective anticancer chemotherapeutic agents associated with acute
and late-stage dose-dependent cardiotoxicity. In the heart, these drugs lead to DNA damage, mitochondrial defective biogenesis and dysfunction that along with oxidative stress cause cardiac cells death and eventually HF [112]. Autophagy is critical for ADR-induced cardiotoxicity [113].

Administration of anthracyclines in mice increases the levels of cardiac and circulating HMGB1, likely released by necrotic cells [72, 113, 114]. Peroxynitrate species formation following Dox treatment regulates HMGB1 expression and release through JNK activation [72]. Injection of BoxA as well as genetic ablation of Tlr4 reduce the cardio-depressive action of Dox by partially abrogating CM apoptosis (Table 2) [72]. ADR reduces the expression of the transcriptional activator Yes-associated protein (YAP) that, in turn, promotes HMGB1 upregulation in cardiomyocyte-like cells [113]. Silencing of HMGB1 reduces ADR-dependent autophagy and apoptosis by downregulating Light chain 3-phosphatidylethanolamine conjugate II (LC3II) and caspase-3, respectively [113].

Higher expression of cardiac HMGB1 exerts a protective effect in the pathogenesis of Dox-induced cardiomyopathy (Table 2). HMGB1-Tg mice treated with Dox show higher survival and attenuated LV dilatation and remodeling [114]. Higher levels of HMGB1 suppress mitochondrial vacuolization and dysfunction and cardiomyocyte apoptosis in response to Dox by upregulating heat shock protein beta 1 that, in turn, prevents caspase-3 activation [114].

**Diabetic cardiomyopathy (DCM)**

MI is the most frequent cause of death in the diabetic population. HF is frequently associated with diabetes mellitus (DM) and, when it occurs independently of hypertension and coronary artery disease, is denominated diabetic cardiomyopathy (DCM). Long-term hyperglycemia triggers myocardial contractile dysfunction caused by cardiomyocyte hypertrophy, apoptosis and interstitial fibrosis [115].

CFs, CMs and macrophages cultured in hyperglycemic concentration of glucose (HG) exhibit enhanced HMGB1 expression [116, 117] and the protein is actively secreted from the nucleus to the extracellular space [117]. HG-dependent activation of the Phosphoinositide-3-kinase (PI3 K)/Protein-chinasi B (AKT) pathway is responsible for the upregulation of HMGB1 levels in CMs [118]. Silencing of HMGB1 or RAGE in these cells attenuates the NF-κB-mediated inflammatory cytokine production induced by HG [116]. Likewise, streptozotocin (STZ)-induced type 1 diabetes mellitus mice exhibit higher myocardial and circulating HMGB1 levels compared with control animals [40, 116, 119, 120]. Inhibition of RAGE or HMGB1, or BoxA administration in mice protects from (STZ)-induced cardiac dysfunction, reducing fibrosis and inflammation (Table 2) [40, 116, 119]. HMGB1 is required for HG-induced CMs apoptosis mediated by caspase-3 and BCL2 Associated X (Bax) activity via Extracellular signal–regulated kinase (ERK)1/2 activation [40]. HMGB1 also directly regulates CF proliferation and the profibrotic activity through MAPKs and AKT pathways [117] or through the reduction of the antiinflammatory cytokine IL-33 via engagement of TLR4 [119, 121]. Recently, Wu et al. showed that interaction of HMGB1 with TLR2 alters the autophagy response in CFs causing an extensive synthesis of collagen I and α-smooth muscle actin (SMA) [119]. In vivo Glycyrhrizin (Gly) interferes with the HMGB1-TLR2 axis and alleviates cardiac fibrosis induced by isoproterenol (ISO) treatment [122]. The anti-oxidative properties of resveratrol reduced HMGB1 upregulation and signaling and ameliorated fibrosis and inflammation in diabetic hearts [120].

Diabetic animals subjected to I/R show an additional enhancement of HMGB1 cardiac and pro-inflammatory expression [95, 116]. Astilbin, a flavonoid compound that attenuates cardiac remodeling after I/R in diabetic rats, prevents HMGB1 upregulation [95]. Treatment of diabetic animals with BoxA early before I/R abrogates RAGE-dependent MAPKs and NF-κB activation and results in an improvement of cardiac contraction and diminished infarct size, inflammation and post-infarct remodeling (Table 2) [116].

**Myocarditis**

Myocarditis refers to inflammation of the heart characterized by infiltration of inflammatory cells after viral, bacterial and protozoan infections [123]. Myocarditis is often an autoimmune reaction as well characterized by antibody-mediated myocardial damage [124]. For these reasons, myocarditis is the most common cause of acute HF and sudden death in young subjects [123, 124].

The role of HMGB1 in the pathogenesis of myocarditis has been evaluated for the first time in a mouse model of experimental autoimmune myocarditis (EAM) induced by inoculation of the cardiac myosin heavy chain (MyHC) peptide in the susceptible BALC/c mice strain [125]. This model replicates CD4+ T-cell-mediated autoimmune diseases and is characterized by myocardial necrosis, inflammatory infiltration and cardiac fibrosis. HMGB1 increased in cardiac tissue and in the blood of EAM mice and its blockage with an anti-HMGB1 antibody reduced infiltration of T helper-17 (Th17) cells, serum levels of inflammatory molecules and cardiac fibrosis [125]. HMGB1 directly affects Th17 cell polarization, differentiation and proliferation [125, 126]. More recently, Bangert et al. set up a murine model of cardiac Troponin I (TnI)-induced EAM [127]. HMGB1 inhibition with a specific antibody or glycyrrhizin decrease TnI-induced cardiac inflammation and dysfunction. Remarkably, HMGB1-Adeno-associated virus (AAV) mice,
characterized by cardiomyocyte specific overexpression of HMGB1 encoded by an adeno-associated virus, exhibit basal cardiac inflammation, fibrosis and dysfunction that were further exacerbated after Tnf immunization [127]. HMGB1 acts via a RAGE-independent mechanism [127] and TLR2 and/or TLR4 may be involved since an upregulation of both receptors is observed in these mice (Table 2) [127].

Sepsis-induced cardiomyopathy

Cardiac dysfunction is a well-documented consequence of sepsis and septic shock [128]. Treatment of animals with LPS upregulates HMGB1 in cardiomyocytes and increases its levels in the bloodstream [129, 130] and both BoxA and glycyrrhizin ameliorate LPS-induced depression of cardiac contractility (Table 2) [130]. LPS promotes HMGB1 secretion via TLR4-dependent PI3 Kγ activation in isolated NMCMs and CFs/myofibroblasts [130]. Activation of PI3 K/ AKT signaling, which prevents cardiac dysfunction during septic cardiomyopathy, is associated to inhibition of cardiac HMGB1 expression and translocation and of inflammation [131, 132].

Idiopathic dilated cardiomyopathy

It is noteworthy that most animal models of dilated cardiomyopathy are related to a specific cause such as MI, aortic constriction, anthracyclines, myocarditis, and diabetes; the role of HMGB1 in these conditions has been addressed above. Idiopathic dilated cardiomyopathy is a clinical diagnosis by exclusion and no preclinical studies have examined HMGB1 in this condition in animal models of spontaneous cardiomyopathy.

HMGB1 as a diagnostic and prognostic biomarker in human cardiac dysfunctions

Acute MI

Several clinical studies have reported elevated levels of circulating HMGB1 after acute MI [82, 133–138]. Goldstein et al. were the first to report that serum HMGB1 levels were significantly elevated in a small number of patients with myocardial ischemia compared to aged- and sex-matched healthy controls [136]. Later, Kohno et al. showed that circulating HMGB1 increased in patients with ST-elevation MI (STEMI) after undergoing percutaneous coronary intervention (PCI), peaking at 12 h after admission, and remaining elevated after 7 days compared to chronic stable angina (CSA) patients [82]. Peak HMGB1 levels independently associated with pump failure, cardiac rupture, in-hospital cardiac death and C-reactive protein (CRP) levels [82]. Furthermore, HMGB1 circulating levels positively correlated with plasma brain natriuretic peptide (BNP) determined 6 months after the infarction [82]. Accordingly, in a larger clinical study, Sørensen et al. reported elevated levels of plasma HMGB1 in a homogeneous group of STEMI patients after PCI when compared to control subjects [138]. Patients who died during the follow-up of 10 months exhibited higher levels of HMGB1 than surviving patients. Increased systemic HMGB1 levels, measured 3 h after hospital admission for STEMI, was also associated with reduced functional recovery after MI measured as heart rate recovery (HRR), peak oxygen consumption (VO2peak) and LV Ejection fraction (LVEF) determined 3–4 weeks after MI [134, 135].

Hashimoto et al. reported a strong association between serum levels of HMGB1 and adverse cardiovascular events after a median follow-up of 49 months in unstable angina (UA) and Non-STEMI (N-STEMI) Japanese patients with MI within 24 h of symptoms onset [137]. HMGB1 had a better ability to separate high- and low-risk subjects than CRP and the authors suggested it might be effective biomarkers for early risk stratification in UA and N-STEMI patients [137]. Finally, Andrassy et al. reported that circulating HMGB1 concentration, 2-4 days after hospital admission, represented a valuable negative prognostic mortality marker in acute coronary syndrome (ACS) patients, comparable to residual LV function, in STEMI and N-STEMI patients [133].

Thus, serum HMGB1 concentration early after the acute MI is predictive of the infarct size and risk of death, and represents a reliable prognostic biomarker for risk stratification and cardiovascular death in infarcted patients. Furthermore, the levels of HMGB1, days after the injury, may relate to the level of inflammation following the initial phase of tissue necrosis, and hence, may represent an early inflammatory prognostic indicator of HF development. The redox forms of HMGB1 released after cardiac injury have not been identified yet, thus further studies in this clinical setting are needed.

Chronic HF

Wang et al. show that elevated serum levels of HMGB1 are associated with systolic HF and worsening of LVEF caused by ischaemic or idiopathic dilated cardiomyopathy in both diabetic and non-diabetic groups of Asian patients [139]. Voltz et al. found that systemic levels of HMGB1 were upregulated also in Caucasian patients with severe HF, irrespective of the underlying cause of the disease (ischemic vs non-ischemic), compared to moderate/no symptoms subjects or healthy controls [140]. HMGB1 showed positive association with several markers and predictors of the disease such as N-terminal prohormone of brain natriuretic peptide (NTproBNP), creatinine levels, white blood cells (WBC) count and New York Heart Association (NYHA)
classification, and was a predictor of all-cause death and heart transplantation [140]. Recently, Liu et al. examined serum HMGB1 amount in Chinese patients with chronic HF due to ischemic cardiomyopathy. HMGB1 levels were higher in HF subjects than in the control group and positively correlated with NTproBNP and NYHA functional class, while negatively correlated with LVEF [141]. Furthermore, HMGB1 was higher in patients who died than survivors after 12-month follow-up [141].

Hence, HMGB1 may be an alternative independent indicator of risk stratification in patients with chronic HF but further studies in more homogenous and larger population are needed.

**Myocarditis**

Bangert et al. found higher levels of HMGB1 in the plasma of a small number of patients diagnosed with acute myocarditis compared to patients without any signs of inflammation [127].

**Conclusion and future perspective**

HMGB1 is an ancestral chromatin-binding protein that during evolution has acquired an additional role as an extracellular “alarmin”. Very recent findings have demonstrated that extracellular functions of HMGB1 depend on its redox state [13, 45]. To date, the role of HMGB1 redox forms in the context of cardiac injuries remains mostly unexplored, opening promising new avenues of investigation in this field. Clearly, oxidative and nitrosative stress following an insult affects the expression, secretion and release of HMGB1 from cardiac cells. It is very likely that different levels of reactive oxygen species (ROS) production during cardiac damage regulates the kinetics of interconversion of fr-HMGB1 to ds-HMGB1 and ox-HMGB1 (Fig. 6), which could in part explain the discrepancies observed after administration of HMGB1 inhibitors in the various experimental models of cardiac injuries. For instance, I/R produces higher amounts of ROS than permanent ligation [142]. Moreover, it is not known which specific HMGB1 redox forms are involved in CMs contractility, hypertrophy and apoptosis, CFs activities or CPCs proliferation and differentiation (Fig. 6). Hence, the selective inhibition of HMGB1 redox forms or the modulation of HMGB1 oxidation could be a strategy to influence cardiac cell functions, limit inflammation and damage and favor heart repair. These are feasible approaches since selective inhibitors for HMGB1 redox forms have been identified (Table 1) and some ligands like Gly or heparin have been shown to modulate its oxidation kinetic [143].

Although extracellular HMGB1 is a risk factor for a number of heart diseases, applying neutralizing antibody or a biological inhibitor of HMGB1 as therapeutic agents is still confronted with a variety of challenges. In particular, several monoclonal antibodies against HMGB1 area available, and several are neutralizing. Some of these may hold clinical promise. However, they need to be optimized for clinical use, and clinical tests have not been initiated so far. BoxA is an effective inhibitor of HMGB1, but the molecule was described decade ago before the implication of HMGB1 in several pathologies was known, and cannot be patented; this alone makes clinical development very unlikely. Small molecules hold more promise, especially if they can be shown to act on specific redox of HMGB1. Glycyrrhizin is widely used in preclinical research, but has a number of drawbacks from the pharmacological point of view. Salicylic acid (SA) inhibits HMGB1, and this may contribute to the pharmacological properties of aspirin, of which SA is a metabolite. However, aspirin is not specific and efficacious enough for use in specific pathologies [15].

Another important point to be addressed concerns the identification of the redox forms of HMGB1 released after cardiac injury in clinical scenarios. Interestingly, specific HMGB1 redox forms appear more informative than total HMGB1 as clinical biomarkers [15, 144]. Likewise, modified HMGB1 forms may be also more informative than total HMGB1 as diagnostic and prognostic biomarker for risk stratification in the setting of acute cardiac insults such as myocardial infarction and myocarditis (Fig. 6). Taken together, these new observations may lead to the development of novel diagnostic and therapeutic strategies. Theoretically, the modified protein could be associated with different disease stages: non-acetylated and fr-HMGB1 could reflect the passive release of HMGB1 soon after injury and hence, the extent of the cardiac tissue loss, whereas acetylated and ds-HMGB1 could reflect active secretion, ongoing tissue inflammation and the presence of infiltrating immune cells.

Finally, how damaged cardiac cells can balance nuclear and extracellular functions of HMGB1 remains unexplored. Muscle regeneration is compromised in Hmgb1−/− mice and skeletal healing after a fracture is impaired in Hmgb1−/− mice [18, 45]. At the cellular levels, the dual location of HMGB1 seems to be functionally complementary; indeed, unstimulated Hmgb1−/− macrophages have low histone content and activate genes associated with chemotaxis and inflammation similar to LPS-stimulated Hmgb1+/+ cells [14], suggesting that chromatin rearrangement caused by HMGB1-dependent nucleosome loss is an important epigenetic event in the cellular response to inflammation. Secretion of HMGB1 in the extracellular matrix implies a partial depletion of the nuclear level of HMGB1. Cells lacking HMGB1 contain fewer nucleosomes and more RNA transcripts genome-wide and have an increased susceptibility to DNA damage [6]. DNA damage by itself triggers HMGB1 translocation.
from nucleus to cytoplasm and this could further increase accumulation of DNA lesions leading to apoptosis. Various type of DNA damage and the activation of the DNA damage response (DDR) is observed in infarcted heart and pressure-overload HF [145]. Preliminary data indicate that maintenance of higher nuclear HMGB1 content protects CMs from apoptosis induced by Dox and detrimental hypertrophic stimuli by preventing DNA oxidative damage [114]. Thus, understanding how cells may preserve a proper level of nuclear HMGB1 to sustain efficient DNA repair may help to understand the progression of cardiac diseases.

In conclusions, further studies are necessary to understand the mechanisms by which extracellular and nuclear HMGB1 affects cardiac inflammation and repair/regeneration and how it can be manipulated to maximize its therapeutic potential in different forms of heart disease.

Acknowledgments This work was supported by funding from Fondazione Cariplo to M.B. and A.R and Centro Cardiologico Monzino-IRCCS (Ricerca Corrente 2017–2018) to A.R.; F.S. was supported by a Fondazione IEO-Monzino Fellowship.

Compliance with ethical standards

Conflict of interest None declared. However, M.E.B. is founder and part owner of HMGBiotech, a company that provides goods and services related to HMGB proteins.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Go AS, Mozaffarian D, Roger VL et al (2014) Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation 129(3):e28–e292. https://doi.org/10.1161/01.cir.0000441139.02102.80

2. Ahuja P, Sdek P, MacLellan WR (2007) Cardiac myocyte cell cycle control in development, disease, and regeneration. Physiol Rev 87(2):521–544. https://doi.org/10.1152/physrev.00032.2006

3. Bergmann O, Braun T (2016) Caught red-handed: cycling cardiomyocytes. Circ Res 118(1):3–5. https://doi.org/10.1161/CIRCRESAHA.115.307936

4. Frangogiannis NG (2014) The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol 11(5):255–265. https://doi.org/10.1038/nrcardio.2014.28

5. Bianchi ME, Agresti A (2005) HMG proteins: dynamic players in gene regulation and differentiation. Curr Opin Genet Dev 15(5):496–506. https://doi.org/10.1016/j.gde.2005.08.007

6. Celona B, Weiner A, Di Felice P et al (2011) Substantial histone reduction modulates genome wide nucleosomal occupancy and global transcriptional output. PLoS Biol 9(6):e1001086. https://doi.org/10.1371/journal.pbio.1001086

7. Liu Y, Prasad R, Wilson SH (2010) HMGB1: roles in base excision repair and related function. Biochim Biophys Acta 1799(1–2):119–130. https://doi.org/10.1016/j.bbamcr.2009.11.008

8. Harris HE, Raucci A (2006) Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep 7(8):774–778. https://doi.org/10.1038/sj.embor.7400759

9. Bianchi ME, Manfredi AA (2007) High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 220:35–46. https://doi.org/10.1111/j.1600-065x.2007.00574.x

10. Venereau E, Cerciotti C, Bianchi ME (2015) DAMPs from cell death to new life. Front Immunol 6:442. https://doi.org/10.3389/fimmu.2015.00422

11. Bonaldi T, Talamo F, Scaffidi P et al (2003) Monocytes hyperacetylate chromatin protein HMG1 to redirect it towards secretory. EMBO J 22(20):5551–5560. https://doi.org/10.1093/emboj/cdg516

12. Tsung A, Tohme S, Billiar TR (2014) High-mobility group box 1 in sterile inflammation. J Intern Med 276(5):425–443. https://doi.org/10.1111/joim.12276

13. Venereau E, Casalgrandi M, Schiraldo M et al (2012) Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 209(9):1519–1528. https://doi.org/10.1084/jem.20120189

14. De Toma I, Rossetti G, Zambrano S et al (2014) Nucleosome loss facilitates the chemotactic response of macrophages. J Intern Med 276(5):454–469. https://doi.org/10.1111/joim.12286

15. Venereau E, De Leo F, Mezzapelle R et al (2016) HMGB1 as biomarker and drug target. Pharmacol Res 111:534–544. https://doi.org/10.1016/j.phrs.2016.06.031

16. Sessa L, Bianchi ME (2007) The evolution of High Mobility Group Box (HMGB) chromatin proteins in multicellular animals. Gene 387(1–2):133–140. https://doi.org/10.1016/j.gene.2006.08.034

17. Calogero S, Grassi F, Aguzzi A et al (1999) The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet 22(3):276–280. https://doi.org/10.1038/10338

18. Lee G, Espirito Santo AL, Zwingenberger S et al (2018) Fully reduced HMGB1 accelerates the regeneration of multiple tissues by transitioning stem cells to GAlert. Proc Natl Acad Sci USA 115(19):E4463–E4472. https://doi.org/10.1073/pnas.1802893115

19. Bianchi ME, Falcioni L, Ferrari S et al (1992) The DNA binding site of HMGB1 protein is composed of two similar segments (HMGB boxes), both of which have counterparts in other eukaryotic regulatory proteins. EMBO J 11(3):1055–1063

20. Rabadi MM, Xavier S, Vasko R et al (2015) High-mobility group box 1 is a novel deacetylation target of Sirtuin1. Kidney Int 87(1):95–108. https://doi.org/10.1038/ki.2014.217

21. Oh YJ, Youn JH, Ji Y et al (2009) HMGB1 is phosphorylated by classical protein kinase C and is secreted by a calcium-dependent mechanism. J Immunol 182(9):5800–5809. https://doi.org/10.4049/jimmunol.0801873

22. Zhang X, Wheeler D, Tang Y et al (2008) Calcium/calmodulin-dependent protein kinase (CaMK IV) mediates nucleocytoplasmic shuttling and release of HMGB1 during lipopolysaccharide stimulation of macrophages. J Immunol 181(7):5015–5023

23. Ito I, Fukazawa J, Yoshida M (2007) Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J Biol Chem 282(22):16336–16344. https://doi.org/10.1074/jbc.M700647200

24. Yang H, Lundback P, Ottosson L et al (2012) Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med 18:250. https://doi.org/10.2119/molmed.2011.100389

25. Bianchi ME (2007) DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81(1):1–5. https://doi.org/10.1189/jlb.0306164

26. Creagh EM, O’Neill LA (2006) TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 27(8):352–357. https://doi.org/10.1016/j.it.2006.06.003

27. Rovere-Querini P, Capobianco A, Scaffidi P et al (2004) HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 5(8):825–830. https://doi.org/10.1038/sj.embor.7400205

28. Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418(6894):191–195. https://doi.org/10.1038/nature00858

29. Gardella S, Andrei C, Ferrera D et al (2002) The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 3(10):995–1001. https://doi.org/10.1093/embo-reports/ kvf198

30. Wang H, Bloom O, Zhang M et al (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285(5425):248–251

31. Lu B, Antoine DJ, Kwan K et al (2014) JAK/STAT1 signaling promotes HMGB1 hyperacylation and nuclear translocation. Proc Natl Acad Sci USA 111(8):3068–3073. https://doi.org/10.1073/pnas.1316925111

32. Lu B, Nakamura T, Inouye K et al (2012) Novel role of PKR in inflammasome activation and HMGB1 release. Nature 488(7413):670–674. https://doi.org/10.1038/nature11290

33. Yang S, Xu L, Yang T et al (2014) High-mobility group box-1 and its role in angiogenesis. J Leukoc Biol 95(4):563–574. https://doi.org/10.1189/jlb.0713412

34. Andersson U, Wang H, Palmblad K et al (2000) High mobility group 1 protein (HMGB-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192(4):565–570
35. Dumitriu IE, Bianchi ME, Bacci M et al (2007) The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol 81(1):84–91. https://doi.org/10.1189/jlb.0306171
36. Schiraldi M, Raucci A, Munoz LM et al (2012) HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med 209(3):551–563. https://doi.org/10.1084/jem.20111739
37. Treutiger CJ, Mullins GE, Johansson AS et al (2003) High mobility group 1 B-box mediates activation of human endothelium. J Intern Med 254(4):375–385
38. Andrassy M, Volz HC, Igwe JC et al (2008) High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 117(25):3216–3226. https://doi.org/10.1161/CIRCULATIONAHA.107.1709331
39. Tsung A, Sahai R, Tanaka H et al (2005) The nuclear factor Ets-1 signalling pathway. J Cell Mol Med 18(11):2311–2320. https://doi.org/10.1111/j.1749-6632.2005.00015.x
40. Wang WK, Lu QH, Zhang JN et al (2014) HMGB1 mediates hyperglycaemia-induced cardiomyocyte apoptosis via ERK/Ets-1 signalling pathway. J Cell Mol Med 18(11):2311–2320. https://doi.org/10.1111/jcm.12399
41. Ulloa L, Batliwalla FM, Anderson U et al (2003) High mobility group box chromosomal protein 1 as a nuclear protein, cytokine, and potential therapeutic target in arthritis. Arthritis Rheum 48(4):876–881. https://doi.org/10.1002/art.10854
42. Maroso M, Balosso S, Ravizza T et al (2010) Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med 16(4):413–419. https://doi.org/10.1038/nm.2127
43. De Mori R, Straino S, Di Carlo A et al (2007) Multiple effects of high mobility group box protein 1 in skeletal muscle regeneration. Arterioscler Thromb Vasc Biol 27(11):2377–2383. https://doi.org/10.1161/ATVBAHA.107.153429
44. Limana F, Germani A, Zacheo A et al (2005) Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. Circ Res 97(8):e73–e83. https://doi.org/10.1161/01.RES.0000186276.06104.04
45. Tirone M, Tran NL, Ceriotti C et al (2018) High mobility group box 1 orchestrates tissue regeneration via CXCR4. J Exp Med 215(1):303–318. https://doi.org/10.1084/jem.20160217
46. Vezzoli M, Castellani P, Corna G et al (2011) High-mobility group box 1 release and redox regulation accompany regeneration and remodeling of skeletal muscle. Antioxid Redox Signal 15(8):2161–2174. https://doi.org/10.1089/ars.2010.3341
47. Straino S, Di Carlo A, Mangoni A et al (2008) High-mobility group box 1 protein in human and murine skin: involvement in wound healing. J Invest Dermatol 128(6):1545–1553. https://doi.org/10.1038/sj.jid.5701212
48. Chavakis E, Hain A, Vinci M et al (2007) High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res 100(2):204–212. https://doi.org/10.1161/01.RES.0000257774.55970.14
49. Meng E, Guo Z, Wang H et al (2008) High mobility group box 1 protein inhibits the proliferation of human mesenchymal stem cells and promotes their migration and differentiation along osteoblastic pathway. Stem Cells Dev 17(4):805–813. https://doi.org/10.1089/scd.2008.027610.1089/scd.2007.0276
50. Palumbo R, Sampaolesi M, De Marchis F et al (2004) Extracellular HMGB1, a signal of tissue damage, induces mesangioblast migration and proliferation. J Cell Biol 164(3):441–449. https://doi.org/10.1083/jcb.200304135
51. Yang H, Hreggvidsdottir HS, Palmblad K et al (2010) A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 107(26):11942–11947. https://doi.org/10.1073/pnas.1003893107
52. Zhu L, Ren L, Chen Y et al (2015) Redox status of high-mobility group box 1 performs a dual role in angiogenesis of colorectal carcinoma. J Cell Mol Med 19(9):2128–2135. https://doi.org/10.1111/jcmm.12577
53. Di Maggio S, Milano G, De Marchis F et al (2017) Non-oxidizable HMGB1 induces cardiac fibroblasts migration via CXCR4 in a CXCL12-independent manner and worsens tissue remodeling after myocardial infarction. Biochim Biophys Acta. https://doi.org/10.1016/j.bbapap.2017.07.012
54. Maugeri N, Rovere-Querini P, Baldini M et al (2014) Oxidative stress elicits platelet/leukocyte inflammatory interactions via HMGB1: a candidate for microvessel injury in systemic sclerosis. Antioxid Redox Signal 20(7):1060–1074. https://doi.org/10.1089/ars.2013.5298
55. Fritz G (2011) RAGE: a single receptor fits multiple ligands. Trends Biochem Sci 36(12):625–632
56. Sessa L, Gatti E, Zeni F et al (2014) The receptor for advanced glycation end-products (RAGE) is only present in mammals, and belongs to a family of cell adhesion molecules (CAMs). PLoS One 9(1):e86903. https://doi.org/10.1371/journal.pone.0086903
57. Kierdorf K, Fritz G (2013) RAGE regulation and signaling in inflammation and beyond. J Leukoc Biol 94(1):55–68. https://doi.org/10.1189/jlb.1012519
58. Kang R, Chen R, Zhang Q et al (2014) HMGB1 in health and disease. Mol Aspects Med 40(1):116. https://doi.org/10.1016/j.mam.2014.05.001
59. Orlova VV, Choi EY, Xie C et al (2007) A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J 26(4):1129–1139. https://doi.org/10.1038/sj.emboj.7601552
60. Penzo M, Molteni R, Suda T et al (2010) Inhibitor of NF-kappa B kinases alpha and beta are both essential for high mobility group box 1-mediated chemotaxis [corrected]. J Immunol 184(8):4497–4509. https://doi.org/10.4049/jimmunol.0903131
61. Raucci A, Cugusi S, Antonelli A et al (2008) A soluble form of the receptor for advanced glycation end-products (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 22(10):3716–3727. https://doi.org/10.1096/fj.10-109033
62. Stark K, Philippi V, Stockhausen S et al (2016) Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice. Blood 128(20):2435–2449. https://doi.org/10.1182/blood-2016-04-710632
63. Leifer CA, Medvedev AE (2016) Molecular mechanisms of regulation of Toll-like receptor signaling. J Leukoc Biol 100(5):927–941. https://doi.org/10.1189/jlb.2MR0316-117RR
64. Park JS, Svetkaupta D, He Q et al (2004) Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279(9):7370–7377. https://doi.org/10.1074/jbc.M306793200
65. Conti L, Lanzardo S, Arigoni M et al (2013) The noninflammatory role of high mobility group box 1/Toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells. FASEB J 27(12):4731–4744. https://doi.org/10.1096/fj.13-230201
66. Qiu Y, Yang J, Wang W et al (2014) HMGB1-promoted and TLR2/4-dependent NK cell maturation and activation take part in rotavirus-induced murine biliary atresia. PLoS Pathog 10(3):e1004011. https://doi.org/10.1371/journal.ppat.1004011
67. Urbanovacite V, Furrhroh BG, Meister S et al (2008) Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 205(13):3007–3018. https://doi.org/10.1084/jem.20081165
68. Herzog C, Lorenz A, Gillmann HJ et al (2014) Thrombomodulin’s lectin-like domain reduces myocardial damage by interfering with HMGB1-mediated TLR2 signalling. Cardiovasc Res 101(3):400–410. https://doi.org/10.1093/cvr/cvt275
69. Mersmann J, Iskandar F, Latsch K, et al (2013) Attenuation of myocardial injury by HMGB1 blockade during ischemia/reperfusion is toll-like receptor 2-dependent. Mediators Inflamm 2013:174168. https://doi.org/10.1155/2013/174168
70. Mittal D, Saccheri F, Venereau E et al (2010) TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J 29(13):2242–2252. https://doi.org/10.1038/emboj.2010.94
71. Yang Z, Deng Y, Su D et al (2013) TLR4 as receptor for HMGB1-mediated acute lung injury after liver ischemia/reperfusion injury. Lab Invest 93(7):792–800. https://doi.org/10.1038/labinvest.2013.66
72. Yao Y, Xu X, Zhang G et al (2012) Role of HMGB1 in doxorubicin-induced myocardial apoptosis and its regulation pathway. Basic Res Cardiol 107(3):267. https://doi.org/10.1007/s00395-012-0267-3
73. Yang H, Wang H, Ju Z et al (2015) MD-2 is required for disulfide HMGB1-dependent TLR4 signalling. J Exp Med 212(1):5–14. https://doi.org/10.1084/jem.20141318
74. He M, Bianchi ME, Coleman TR et al (2018) Exploring the biological functional mechanism of the HMGB1/TLR4/MD-2 complex by surface plasmon resonance. Mol Med 24(1):21. https://doi.org/10.1186/s12002-018-0023-8
75. Kim S, Kim SY, Prihis JP et al (2013) Signaling of high mobility group box 1 (HMGB1) through toll-like receptor 4 in macrophages requires CD14. Mol Med 19:88–98. https://doi.org/10.2119/molmed.2012.00306
76. Hummel S, Van Aken H, Zarbock A (2014) Inhibitors of CXCl chemokine receptor type 4: putative therapeutic approaches in inflammatory diseases. Curr Opin Hematol 21(1):29–36. https://doi.org/10.1097/MOH.0000000000000002
77. Campana L, Bosurgi L, Bianchi ME et al (2009) Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells. J Leukoc Biol 86(3):609–615. https://doi.org/10.1189/jlb.0908576
78. Aneja RK, Alcamo AM, Cummings J, et al (2018) Lack of benefit on brain edema, blood–brain barrier permeability, or cognitive outcome in global inducible high mobility group box 1 protein expression via the PI3 K/mTORC1 Inhibition. J Cell Physiol. https://doi.org/10.1002/jcp.25576
79. Limana F, Esposito G, Fasanaro P et al (2013) Transcriptional profiling of HMGB1-induced myocardial repair identifies a key role for Notch signaling. Mol Ther 21(10):1841–1851. https://doi.org/10.1038/mt.2013.137
80. Rossini A, Zacheo A, Mocini D et al (2008) HMGB1-stimulated human primary cardiac fibroblasts exert a paracrine action on human and murine cardiac stem cells. J Mol Cell Cardiol 44(4):683–693. https://doi.org/10.1016/j.yjmcc.2008.01.009
81. Takahashi K, Fukushima S, Yamahara K et al (2008) Modulated inflammation by injection of high-mobility group box 1 recovering post-infarction chronically failing heart. Circulation 118(14 Suppl):S106–S114. https://doi.org/10.1161/CIRCULATIONAHA.107.757443
82. Limana F, Esposito G, D’Arcangelo D et al (2011) HMGB1 attenuates cardiac remodelling in the failing heart via enhanced cardiac regeneration and mir-206-mediated inhibition of TIMP-3. PLoS One 6(6):e19845. https://doi.org/10.1371/journal.pone.0019845
83. van Zuylen VL, den Haan MC, Geutskens SB et al (2015) Post-myocardial infarct inflammation and the potential role of cell therapy. Cardiovasc Drugs Ther 29(1):59–73. https://doi.org/10.1007/s10557-014-6568-z
84. Loukili N, Rosenblatt-Velin N, Li J et al (2011) Peroxynitrite induces HMGB1 release by cardiac cells in vitro and HMGB1 upregulation in the infarcted myocardium in vivo. Cardiovasc Res 89(3):586–594. https://doi.org/10.1093/cvr/cvq373
85. Oozawa S, Mori S, Kanke T et al (2008) Effects of HMGB1 on ischemia-reperfusion injury in the rat heart. Circ J 72(7):1178–1184
86. Xu H, Yao Y, Su Z et al (2011) Endogenous HMGB1 contributes to ischemia-reperfusion-induced myocardial apoptosis by potentiating the effect of TNF-α/alpha/JNK. Am J Physiol Heart Circ Physiol 300(3):H913–H921. https://doi.org/10.1152/ajpheart.00703.2010
87. Tian Y, Pan D, Chordia MD et al (2016) The spleen contributes importantly to myocardial infarct exacerbation during post-ischemic reperfusion in mice via signaling between cardiac HMGB1 and splenic RAGE. Basic Res Cardiol 111(6):62. https://doi.org/10.1007/s00395-016-0583-0
88. Ferdinandy P, Schulz R (2003) Nitric oxide, superoxide, and peroxynitrite in myocardial ischemia-reperfusion injury and preconditioning. Br J Pharmacol 138(4):532–543. https://doi.org/10.1038/sj.bjp.0705080
89. Diao H, Kang Z, Han F et al (2014) Astilbin protects diabetic rat heart against ischemia/reperfusion injury via blockade of HMGB1-dependent NF-kappaB signaling pathway. Food Chem Toxicol 63:104–110. https://doi.org/10.1016/j.fct.2013.01.045
90. Dong LY, Chen F, Xu M et al (2018) Quercetin attenuates myocardial ischemia-reperfusion injury via downregulation of the HMGB1-TLR4-NF-kappaB signaling pathway. Am J Transl Res 10(5):1273–1283
91. Hu X, Zhou X, He B et al (2010) Minocycline protects against myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein expression in rats. Eur J Pharmacol 638(1–3):84–89. https://doi.org/10.1016/j.ejphar.2010.03.059
92. Wang WL, Zhang SP, Zhu HB et al (2012) Cardioprotection of Asperosaponin X on experimental myocardial ischemia injury. Int J Cardiol 155(3):430–436. https://doi.org/10.1016/j.ijcard.2011.06.010
93. Tong S, Zhang L, Joseph J et al (2018) Celestatropretreatment attenuates myocardial ischemia/reperfusion injury by inhibiting high mobility group box 1 protein expression via the PI3 K/
101. Wang N, Min X, Li D et al (2012) Geranylgeranylacetone protects against myocardial ischemia and reperfusion injury by inhibiting high-mobility group box 1 protein release and protects against rat myocardial ischemia/reperfusion injury in vivo. Mol Med Rep 5(2):521–524. https://doi.org/10.3892/mmr.2011.666

102. Wang XY, Dong WP, Bi SH et al (2013) Protective effects of preconditioning with high mobility group box 1 protein in rats. Mol Med Rep 32(2):365–372. https://doi.org/10.3892/ijmr.2013.1386

103. Hu X, Jiang H, Cui B et al (2010) Preconditioning with high mobility group box 1 protein protects against myocardial ischemia-reperfusion injury. Int J Cardiol 145(1):111–112. https://doi.org/10.1016/j.ijcard.2009.05.057

104. Abeyama K, Stern DM, Ito Y et al (2005) The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 115(5):1267–1274. https://doi.org/10.1172/JCI22782

105. Abarbanell AM, Hartley JA, Herrmann JL et al (2011) Exogenous high-mobility group 1 box improves myocardial recovery after acute global ischemia/reperfusion injury. Surgery 149(3):329–335. https://doi.org/10.1016/j.surg.2010.07.002

106. van Berlo JH, Maillet M, Molkentin JD (2013) Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest 123(1):37–45. https://doi.org/10.1172/JCI62839

107. Jia Z, Xue R, Liu G, et al (2014) HMGB1 Is Involved in the Protective Effect of the PPAR alpha Agonist Fenofibrate against Cardiac Hypertrophy. PPAR Res 2014:541394. https://doi.org/10.1155/2014/541394

108. Lin H, Shen L, Zhang X et al (2016) HMGB1-RAGE axis makes no contribution to cardiac remodeling induced by pressure-overload. PLoS One 11(6):e0158514. https://doi.org/10.1371/journal.pone.0158514

109. Zhang L, Liu M, Jiang H et al (2016) Extracellular high-mobility group box 1 mediates pressure overload-induced cardiac hypertrophy and heart failure. J Cell Mol Med 20(3):459–470. https://doi.org/10.1111/jcmm.12743

110. Funayama A, Shishido T, Netsu S et al (2013) Cardiac nuclear high mobility group box 1 prevents the development of cardiac hypertrophy and heart failure. Cardiovasc Res 99(4):657–664. https://doi.org/10.1093/cvr/cvt128

111. Su FF, Shi MQ, Guo WG et al (2012) High-mobility group box 1 induces calcineurin-mediated cell hypertrophy in neonatal rat ventricular myocytes. Mediators Inflamm 2012:805149. https://doi.org/10.1155/2012/805149

112. Vejpongsa P, Yeh ET (2014) Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol 64(9):938–945. https://doi.org/10.1016/j.jacc.2014.06.1176

113. Luo P, Zhu Y, Chen M et al (2018) HMGB1 contributes to adriamycin-induced cardiotoxicity via up-regulating autophagy. Toxicol Lett 292:115–122. https://doi.org/10.1016/j.toxlet.2018.04.034

114. Narumi T, Shishido T, Otaki Y et al (2015) High-mobility group box 1-mediated heat shock protein beta 1 expression attenuates mitochondrial dysfunction and apoptosis. J Mol Cell Cardiol 82:1–12. https://doi.org/10.1016/j.yjmcc.2015.02.018

115. Williams LJ, Nye BG, Wende AR (2017) Diabetes-related cardiac dysfunction. Endocrinol Metab (Seoul) 32(2):171–179. https://doi.org/10.3803/EnM.2017.32.2.171

116. Volz HC, Seidel C, Laohachewin D et al (2010) HMGB1: the missing link between diabetes mellitus and heart failure. Basic Res Cardiol 105(6):805–820. https://doi.org/10.1007/s00395-010-0114-3

117. Wang WK, Wang B, Lu QH et al (2014) Inhibition of high-mobility group box 1 improves myocardial fibrosis and dysfunction in diabetic cardiomyopathy. Int J Cardiol 172(1):202–212. https://doi.org/10.1016/j.ijcard.2014.01.011

118. Song J, Liu Q, Tang H et al (2016) Activation of PI3Kgamma/Akt pathway increases cardiomyocyte HMGB1 expression in diabetic environment. Oncotarget 7(49):80803–80810. https://doi.org/10.18632/oncotarget.13096

119. Tao A, Song J, Lan T et al (2015) Cardiomyocyte-fibroblast interaction contributes to diabetic cardiomyopathy in mice: Role of HMGB1/TLR4/IL-33 axis. Biochim Biophys Acta 1852(10 Pt A):2075–85. https://doi.org/10.1016/j.bbadis.2015.07.015

120. Wu H, Sheng ZQ, Xie J et al (2016) Reduced HMGB1-mediated pathway and oxidative stress in resveratrol-treated diabetic mice: a possible mechanism of cardioprotection of resveratrol in diabetes mellitus. Oxid Med Cell Longev 2016:9836860. https://doi.org/10.1155/2016/9836860

121. Sanada S, Hakuno D, Higgins LJ et al (2007) IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 117(6):1538–1549. https://doi.org/10.1172/JCI30634

122. Wu RN, Yu TY, Zhou JC et al (2018) Targeting HMGB1 ameliorates cardiac fibrosis through restoring TLR2-mediated autophagy suppression in myocardial fibroblasts. Int J Cardiol 267:156–162. https://doi.org/10.1016/j.ijcard.2018.04.103

123. Su Z, Liu PP, Cooper LT Jr (2012) Myocarditis. Lancet 379(9781):738–747. https://doi.org/10.1016/S0140-6736(11)60648-X

124. Comarmond C, Cacoub P (2017) Myocarditis in auto-immune or auto-inflammatory diseases. Autoimmun Rev. https://doi.org/10.1016/j.autrev.2017.05.021

125. Su Z, Sun C, Zhou C et al (2011) HMGB1 blockade attenuates experimental autoimmune myocarditis and suppresses Th17-cell expansion. Eur J Immunol 41(12):3586–3595. https://doi.org/10.1002/eji.201141879

126. Su Z, Yin J, Wang T et al (2014) Up-regulated HMGB1 in EAM directly led to collagen deposition by a PKCbeta/Erk1/2-dependent pathway: cardiac fibroblasts/myofibroblast might be another source of HMGB1. J Cell Mol Med 18(9):1740–1751. https://doi.org/10.1111/jcmm.12324

127. Bangert A, Andrazy M, Muller AM et al (2016) Critical role of RAGE and HMGB1 in inflammatory heart disease. Proc Natl Acad Sci USA 113(2):E155–E164. https://doi.org/10.1073/pnas.1522881113

128. Merx MW, Weber C (2007) Sepsis and the heart. Circulation 116(7):793–802. https://doi.org/10.1161/CIRCULATIONAHA.106.678359

129. Hagiwara S, Iwasaka H, Uchino T et al (2008) High mobility group box 1 induces a negative inotropic effect on the left ventricle in an isolated rat heart model of septic shock: a pilot study. Circ J 72(6):1012–1017

130. Xu H, Su Z, Wu J et al (2010) The alarmin cytokine, high mobility group box 1, is produced by viable cardiomyocytes and mediates the lipopolysaccharide-induced myocardial dysfunction via a TLR4/phosphatidylinositol 3-kinase gamma pathway. J Immunol 184(3):1492–1498. https://doi.org/10.4049/jimmunol.0902660

131. An R, Zhao L, Xi C et al (2016) Melatonin attenuates sepsis-induced cardiac dysfunction via a PI3 K/Akt-dependent mechanism. Basic Res Cardiol 111(1):8. https://doi.org/10.1007/s00395-015-0526-1
The Janus face of HMGB1 in heart disease: a necessary update

132. Li C, Hua F, Ha T et al (2012) Activation of myocardial phosphoinositide-3-kinase p110alpha ameliorates cardiac dysfunction and improves survival in polymicrobial sepsis. PLoS One 7(9):e44712. https://doi.org/10.1371/journal.pone.0044712

133. Andrassy M, Volz HC, Riedle N et al (2011) HMGB1 as a predictor of infarct transmurality and functional recovery in patients with myocardial infarction. J Intern Med 270(3):245–253. https://doi.org/10.1111/j.1365-2796.2011.02369.x

134. Cirillo P, Giallauria F, Pacileo M et al (2009) Increased high mobility group box-1 protein levels are associated with impaired cardiopulmonary and echocardiographic findings after acute myocardial infarction. J Card Fail 15(4):362–367. https://doi.org/10.1016/j.cardfail.2008.11.010

135. Giallauria F, Cirillo P, Lucci R et al (2010) Autonomic dysfunction is associated with high mobility group box-1 levels in patients after acute myocardial infarction. Atherosclerosis 208(1):280–284. https://doi.org/10.1016/j.atherosclerosis.2009.07.025

136. Goldstein RS, Gallowitsch-Puerta M, Yang L et al (2006) Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 25(6):571–574. https://doi.org/10.1097/01.shk.0000209540.99176.72

137. Hashimoto T, Ishii J, Kitagawa F et al (2012) Circulating high-mobility group box 1 and cardiovascular mortality in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis 221(2):490–495. https://doi.org/10.1016/j.atherosclerosis.2012.01.040

138. Sorensen MV, Pedersen S, Mogelvang R et al (2011) Plasma high-mobility group box 1 levels predict mortality after ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 4(3):281–286. https://doi.org/10.1016/j.jcin.2010.10.015

139. Wang LJ, Lu L, Zhang FR et al (2011) Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure. Eur J Heart Fail 13(4):440–449. https://doi.org/10.1093/eurjhf/hfq231

140. Volz HC, Laohachewin D, Schellberg D et al (2012) HMGB1 is an independent predictor of death and heart transplantation in heart failure. Clin Res Cardiol 101(6):427–435. https://doi.org/10.1007/s00392-011-0409-x

141. Liu T, Zhang DY, Zhou YH et al (2015) Increased serum HMGB1 level may predict the fatal outcomes in patients with chronic heart failure. Int J Cardiol 184:318–320. https://doi.org/10.1016/j.ijcard.2015.02.088

142. Vandervelde S, van Amerongen MJ, Tio RA et al (2006) Increased inflammatory response and neovascularization in reperfused vs. non-reperfused murine myocardial infarction. Cardiovasc Pathol 15(2):83–90. https://doi.org/10.1016/j.carpath.2005.10.006

143. Zandarashvili L, Sahu D, Lee K et al (2013) Real-time kinetics of high-mobility group box 1 (HMGB1) oxidation in extracellular fluids studied by in situ protein NMR spectroscopy. J Biol Chem 288(17):11621–11627. https://doi.org/10.1074/jbc.M113.449942

144. Walker LE, Frigerio F, Ravizza T et al (2017) Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy. J Clin Invest 127(6):2118–2132. https://doi.org/10.1172/JCI92001

145. Higo T, Naito AT, Sumida T, et al (2017) DNA single-strand break-induced DNA damage response causes heart failure. Nat Commun 8:15104. https://doi.org/10.1038/ncomms15104